Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
27. September 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07. September 2022 17:36 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
25. August 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Oyster Point Pharma To Attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022
15. August 2022 08:00 ET
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
08. August 2022 16:03 ET
|
Oyster Point Pharma, Inc.
Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage...